Key considerations for adapting software systems to leverage AI and ML in biologics. Learn about data organization, scalability, metadata, processing...
This post explores the steps that can sometimes trap therapeutic discovery teams and CROs on the path of building their own bioregistry without...
Advances in artificial intelligence (AI) and machine learning (ML) have shown significant promise is in the de novo generation of therapeutic...
Artificial intelligence (AI) and machine learning (ML) are playing increasingly significant roles in the field of drug discovery.
It has never been more important to organize, standardize, and centralize data collection in the pursuit of new medicines.
NGS offers an approach for identifying and extracting variable domain heavy-chain (VHH) regions from camelid B-cells.
In the search for new therapies that can treat a wide variety of neurodegenerative diseases, scientists are exploring the potential of nanobodies.
Nanobodies, also known as single-domain antibodies or VHHs, are small, highly stable, and specific antibody fragments.
In pharmacokinetics, standard curves are used to determine the concentration of a drug in biological fluids such as blood or plasma.
The sunk cost fallacy can affect our decision making around LIMS, other software, and antibody discovery technology purchases.